Dissecting the Role of Multiple Reductases in Bioactivation and Cytotoxicity of the Antitumor Agent 2,5-Diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1)

Chao Yan, Jadwiga K. Kepa, David Siegel, Ian J. Stratford, and David Ross

Department of Pharmaceutical Sciences and Cancer Center, School of Pharmacy, University of Colorado Denver, Denver, Colorado (C.Y., J.K.K., D.S., D.R.); and School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, United Kingdom (I.J.S.)

Received July 8, 2008; accepted September 15, 2008

ABSTRACT

2,5-Diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1) is a novel antitumor diaziridinyl benzoquinone derivative designed to be bioactivated by the two-electron reductase NAD(P)H:quinone oxidoreductase (NQO1) and is currently in clinical trials. NQO1 is expressed at high levels in many solid tumors. RH1 cytotoxicity has been shown previously to be NQO1-dependent. The purpose of this study was to investigate whether other reducing enzymes such as cytochrome b5 reductase (b5R), cytochrome P450 reductase (P450R), dihydronicotinamide riboside:quinone oxidoreductase 2 (NQO2), and xanthine oxidase/xanthine dehydrogenase (XO/XDH) also contribute to the bioactivation and cytotoxicity of RH1 in human tumor cells. For these studies, we established a series of stable MDA468 breast cancer cell lines overexpressing various levels of NQO1, b5R, P450R, and NQO2 and compared RH1-induced growth inhibition [3-(4,5-dimethylthiazol-2,5-diphenyl)tetrazolium and sulforhodamine B analysis] and interstrand DNA cross-linking (comet analysis) in both parental MDA468 cells and transfected clones. RH1 toxicity correlated with NQO1 and NQO2 but not with either b5R or P450R activity levels in the respective series of transfected MDA468 cell clones. Enzymatic assays showed that RH1 was an in vitro substrate for xanthine oxidase. However, XO/XDH protein and activity could not be detected in a variety of human tumor cell lines. These studies suggest that NQO1 and NQO2 are the principal enzymatic determinants of RH1 bioactivation in MDA468 tumor cells and that b5R, P450R, and XD/XO are unlikely to play major roles. Our studies also suggest that NQO2 may be particularly relevant as a bioactivation system for RH1 in NQO1-deficient tumors such as leukemias and lymphomas.

2,5-Diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1) is a novel antitumor diaziridinyl benzoquinone derivative that is currently in phase I clinical trials. This drug was designed to be bioreductively activated by the two-electron reductase NAD(P)H:quinone oxidoreductase (NQO1) and is currently in clinical trials. NQO1 is expressed at high levels in many solid tumors. RH1 cytotoxicity has been shown previously to be NQO1-dependent. The purpose of this study was to investigate whether other reducing enzymes such as cytochrome b5 reductase (b5R), cytochrome P450 reductase (P450R), dihydronicotinamide riboside:quinone oxidoreductase 2 (NQO2), and xanthine oxidase/xanthine dehydrogenase (XO/XDH) also contribute to the bioactivation and cytotoxicity of RH1 in human tumor cells. For these studies, we established a series of stable MDA468 breast cancer cell lines overexpressing various levels of NQO1, b5R, P450R, and NQO2 and compared RH1-induced cytotoxic species capable of alkylating and cross-linking DNA (Walton et al., 1991; Fisher et al., 1992; Cummings et al., 1998). RH1 is a very efficient substrate for NQO1, and reduction by NQO1 to the hydroquinone form results in the activation of the aziridine rings and subsequent DNA alkylation and interstrand cross-linking (Ward et al., 2000; Dehn et al., 2005). NQO1 has been shown to be expressed at high levels in some normal tissue but also in many human solid tumors including lung, colon, pancreas, and breast (Cresteil and Jaiswal, 1991; Malkinson et al., 1992; Mikami et al., 1998). Because RH1 is a very efficient substrate for NQO1, it was considered an ideal agent to be used in an NQO1-directed tumor-targeting strategy. RH1 has demonstrated significant antitumor activity both in vitro (Winski et al., 1998, 2001) and in vivo (Cummings et al., 2003; Dehn et al., 2004). Although RH1 was discovered to be effectively activated by...
NQO1, it has long been suspected that other reductases such as the two-electron reductases NRH:quinone oxidoreductase 2 (NQO2, EC 1.10.99.2), xanthine dehydrogenase (XDH, EC 1.1.1.204), or the one-electron reductases NADH:cytochrome b$_5$ reductase (b$_5$R, EC 1.6.2.2), NADPH:cytochrome P450 reductase (P450R, EC 1.6.2.4), and xanthine oxidase (XO, EC 1.1.3.22) may also contribute to the bioactivation and cytotoxicity of RH1 in tumor cells. Many antitumor quinones, which exert their toxicity via NQO1, are also substrates for the above reductases. Quinones can be reduced to hydroquinones via two-electron reduction. They can also be reduced by one-electron reductases to semiquinones, which can then undergo redox cycling in the presence of oxygen, generating superoxide anion and hydrogen peroxide (Powis, 1989). Mitomycin C and E09 have been shown to be substrates for one-electron reductases such as P450R, b$_5$R, and XO, and the generation of oxidative stress after reduction by one-electron reductases has been shown to contribute to the overall cytotoxicity of these drugs (Pan et al., 1984; Bligh et al., 1990; Hodnick and Sartorelli, 1993; Saunders et al., 2000). Whether RH1 is bioactivated by one-electron reductases is still an open question. Recent studies have shown that RH1 could serve as a substrate for P450R (Hasinoff et al., 2006; Begleiter et al., 2007). However, overexpression of P450R in two human breast cancer cell lines, T47D (Begleiter et al., 2007) and MDA-MB231 (Kim et al., 2004), did not render cells more sensitive to RH1 cytotoxicity. A study of RH1 two human breast cancer cell lines, T47D (Begleiter et al., 1990; Hodnick and Sartorelli, 1993; Saunders et al., 2000). Whether RH1 is bioactivated by one-electron reductases is still an open question. Recent studies have shown that RH1 could serve as a substrate for P450R (Hasinoff et al., 2006; Begleiter et al., 2007). However, overexpression of P450R in two human breast cancer cell lines, T47D (Begleiter et al., 2007) and MDA-MB231 (Kim et al., 2004), did not render cells more sensitive to RH1 cytotoxicity. A study of RH1 toxicity in the NCI 60 tumor cell line found a high sensitivity to RH1 in leukemia and lymphoma cell lines, which have very low or absent NQO1 activity (Tudor et al., 2005). These findings suggest that, in addition to activation by NQO1, RH1-induced cytotoxicity might also involve alternative pathways. In this study, we investigated the contribution of multiple one- and two-electron reductases to RH1 induced cytotoxicity.

Materials and Methods

Materials. Cytochrome c, 2,6-dichlorophenol-indophenol (DCPIP), dicoumarol, menadione, 3-(4,5-dimethylthiazol-2-5-diphenyl)tetrazo- lium (MTT), NADH, NADPH, propidium iodide, resveratrol, sulfora- hodamine B (SRB), trichloroacetic acid, xanthine, xanthine oxidase, and all other chemicals were purchased from Sigma Chemical Co. (St. Louis, MO). Dihydronicotinamide riboside (NRH) was prepared by the phosphodiesterase treatment of NADH to generate dihydronicotinamide mononucleotide, which was then treated with alkaline phosphatase to remove the phosphate group using a method reported previously (Friedlos et al., 1992). NRH was then purified from the reaction mixture by reverse-phase HPLC. RH1 was supplied by the NCI (NCS697726), and stock solution was prepared in DMSO.

Cell Culture and Transfection. The human breast cancer cell line MDA-MB-468 (MDA468) was obtained from the American Type Culture Collection (Manassas, VA) and is deficient in NQO1 activity as a result of a homozygous expression of the NQO1$^{-}$ polymorphism. Cells were grown in RPMI 1640 medium supplemented with 10% (v/v) fetal bovine serum, 2 mML-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin. Cells were maintained in a humidified incubator containing 5% carbon dioxide at 37°C. MDA468 cells were stably transducted by electroporation with either the CMV-driven expression vector pDNA 3.9 (Invitrogen, Carlsbad, CA), containing human wtNQO1 cDNA, or the EF-1a-driven IRES expression vector containing human P450R cDNA (a kind gift from Dr. A. V. Patterson, University of Auckland, Auckland, New Zealand), human b$_5$R cDNA, or human NQO2 cDNA. All of the selected clones (NQO1, b$_5$R, P450R-, and NQO2-transfected) were analyzed by measuring both protein levels (immunoblotting) and by measuring enzymatic activities.

Enzyme Activity Assays. Exponentially growing cells (approximately 5 × 10$^6$ total cells) were harvested into 100 µl of 25 mM Tris-HCl, pH 7.4, containing 250 mM sucrose and 5 µM FAD, followed by probe sonication on ice. Supernatant from the sonicate was recovered after centrifugation, and protein concentration was determined using the method of Lowry (Lowry et al., 1951).

NQO1 activity was measured by following the NADH-dependent reduction of DCPIP at 600 nm in a spectrophotometer (Beckman-Coulter, Fullerton, CA) (ERNER, 1987). Reactions (1 ml) contained 25 µM Tris-HCl, pH 7.4, 0.7 mg/ml bovine serum albumin, 0.2 mM NADH, and 40 µM DCPIP. Reactions were started by the addition of a small volume (5–10 µl) of cell supernatant, and the linear decrease in absorbance was monitored at 600 nm for 1 min at 30°C. Reactions were performed in the absence and presence of 20 µM dicumarol. NQO1 activity is defined as the dicumarol-inhibitable reduction of 2,6-dichlorophenol-indophenol, calculated based on an extinction coefficient of 21 mM$^{-1}$ cm$^{-1}$ and expressed as nanomoles of DCPIP reduced per minute per milligram of protein.

NQO2 activity was measured as NRH-dependent menadione reductase activity using MTT as the final electron acceptor (Wu et al., 1997). The assay mixture contained 50 mM phosphate buffer, pH 7.4, 200 µM NRH, 10 µM menadione, and 0.25 mg/ml MTT. Reactions were initiated with the addition of a small volume of cell supernatant, and the linear increase in absorbance with time was recorded at 578 nm for 5 min. Reactions were performed in the absence and presence of 10 µM quercetin, a confirmed inhibitor of NQO2 (Wu et al., 1997). NQO2 activity was defined as the quercetin-inhibitable reduction of MTT, calculated based on an extinction coefficient of 13 mM$^{-1}$ cm$^{-1}$ and expressed as nanomoles of MTT formazan per minute per milligram of protein.

P450R activity was measured as NADPH-dependent reduction of cytochrome c at 550 to 540 nm (Vermilion and Coon, 1978). Reactions (1 ml) contained 300 mM phosphate buffer, pH 7.6, 0.1 mM EDTA, 100 µM NADPH, and 40 µM cytochrome c. Reactions were started by the addition of cytochrome c, and the linear increase in absorbance with time was recorded at 550 to 540 nm for 2 min at 30°C. P450R activity was calculated based on an extinction coefficient of 21 mM$^{-1}$ cm$^{-1}$ and expressed as nanomoles of cytochrome c reduced per minute per milligram of protein.

b$_5$R activity was measured as NADH:ferricyanide reductase at 420 nm (Mihara and Sato, 1978). Reactions (1 ml) contained 110 mM MOPS buffer, pH 7.0, 0.1 mM EDTA, 100 µM NADH, and 200 µM potassium ferricyanide. Reactions were started by the addition of NADH, and the linear decrease in absorbance with time was recorded at 420 nm for 3 min at 30°C. b$_5$R activity was calculated based on an extinction coefficient of 1.02 mM$^{-1}$ cm$^{-1}$ and expressed as nanomoles of potassium ferricyanide reduced per minute per milligram of protein.

XO and XDH activities were determined spectrophotometrically (Stirpe and Della Corte, 1969) by measuring the rate of uric acid formation from xanthine at 295 nm in the absence of NAD$^{+}$ (XO activity) and the rate of NADH formation at 340 nm in the presence of NAD$^{+}$ (XDH activity). XO/XDH activities were also determined fluorometrically by measuring the production of the fluorescent isoxanthopterin from the nonfluorescent petrine, as described previously (Beckman et al., 1989).

Measurement of Oxygen Consumption. Oxygen consumption was measured using a Clark electrode in a 3-ml reaction at 37°C. Cells were collected, counted, and a total of 2 × 10$^6$ cells were resuspended in 3 ml of complete media. Dissolved oxygen content in the 3-ml reaction system was monitored for 10 min to determine basal oxygen consumption rate and an additional 10 min after the injection of 25 µM menadione into the system. Rates of oxygen consumption were determined from linear regions of the oxygraph.
over 5 min. Dissolved oxygen concentrations were adjusted for temperature (37°C) and altitude (5280 feet).

**Growth Inhibition Assay.** Growth inhibition was measured using both the MTT colorimetric assay (Mosmann, 1983) and the SRB colorimetric assay (Vichai and Kirtikara, 2006) to ensure similar results using two different endpoints (MTT, mitochondrial activity; SRB, total cellular protein). For the MTT assay, cells were seeded into triplicate 96-well plates at 2000 cells/well and allowed to attach for 16 h. Cells were then treated with RH1 in complete medium for 2 h followed by incubation with drug-free medium for an additional 72 h at 37°C. Medium was removed by aspiration, and MTT (50 μg/ml of medium (50 μl)) was added to each well and incubated for a further 4 h. Cell viability was determined by measuring the cellular reduction of MTT to the crystalline formazan product, which was dissolved by the addition of 100 μl of DMSO. Optical density was determined at 550 nm using a Thermomax microplate reader (Molecular Devices, Sunnyvale, CA). The IC₅₀ values were defined as the concentration of RH1 that resulted in 50% reduction in cell number compared with the DMSO treated control.

In the SRB assay, drug treatment procedures were identical with the MTT assay, except that cells were seeded at 5000 cells/well. At the end of 72-h incubation with drug-free medium, medium was removed, and cells were fixed with 10% (w/v) trichloroacetic acid, stained with 0.4% (w/v) sulfurphamide B (dissolved in 1% (v/v) acetic acid), and the protein-bound dyes were then dissolved in 10 mM Tris base solution, and absorption at 565 nm was determined using a Thermomax microplate reader.

**Comet Assay.** The inhibition of the colony-forming ability of MDA468 and NQO1/NQO2-transfected clones was assayed using the clonogenic assay as described previously (Winski et al., 2001). In brief, 800 cells in a 100-mm plate were treated with RH1 for 2 h followed by incubation in fresh medium for 10 days. Colonies were stained with crystal violet and counted manually.

**Comet Assay.** DNA damage was evaluated using the single-cell gel electrophoresis method, commonly known as the alkaline comet assay, as described previously (Tice et al., 2000), including a modified version (Ward et al., 1997) to detect DNA cross-linking. In brief, cells were seeded in six-well plates at 1 × 10⁵ cells/well and were allowed to attach for 16 h. After drug treatment, cells were harvested, and 1 × 10⁴ cells were then subjected to the comet assay. Comet slides were stained with phosphatidylinositol and viewed using fluorescence microscopy under a Nikon invert microscope (Eclipse TE300; Nikon, Tokyo, Japan) at 20× magnification. Images were captured using an attached CoolSNAP ES charge-coupled device camera. One hundred cells, 50 each on duplicate slides, were captured and scored using a software package (Komet Version 5; Kinetic Imaging, Belfast, UK). The tail moment was recorded for each comet as an indication of the extent of DNA single-strand damage. The percentage of DNA in the comet tail was also recorded and presented as a supplementary table (Table S2).

For measurement of DNA cross-linking, a fixed amount of single-strand breaks was induced after treatment into control and RH1-treated cells at each concentration point by incubating with 200 μM H₂O₂ for 20 min on ice. Cross-linked DNA is unable to migrate from the head of the comet, and the extent of DNA cross-linking can be indirectly measured by analyzing the relative reduction of DNA migration induced by H₂O₂ compared with untreated H₂O₂ controls.

**Metabolism of RH1 by XO.** Metabolism of RH1 by XO under hypoxic conditions (RH1 competes with oxygen as electron acceptor) was performed in a sealed cuvette. The enzyme reaction mixture (1 ml) contained 100 mM phosphate buffer, pH 7.8, 0.2 mM xanthine, and 25 μM xanthine oxidase (20 μl, diluted in phosphate buffer). RH1 was first diluted in 100 mM phosphate buffer and then added to the reaction mixture. Hypoxic conditions were established by flushing the phosphate buffer and xanthine mixture with high-purity argon for 5 min in a sealed cuvette. Reactions were carried out with a stream of argon gas gently bubbling the surface of the mixture throughout the experiment. The reaction was initiated by injection of xanthine oxidase and RH1. Uric acid formation from xanthine was monitored by measuring the increase in absorbance at 294 nm for 10 min at 30°C using an HP8452 spectrophotometer ( Hewlett Packard, Palo Alto, CA); RH1 consumption was measured as the decrease in absorbance at 326 nm simultaneously. For allopurinol inhibition of XO, the enzyme was preincubated with 50 μM allopurinol for 10 min before injection into the reaction system.

**Metabolism of RH1 by NQO2.** Metabolism of RH1 by NQO2 was analyzed by HPLC as described previously (Beall et al., 1998). The reaction mixture contained 50 mM potassium phosphate buffer, pH 7.4, 1 mg/ml bovine serum albumin, 200 μM NRH, 50 μM RH1, and 0.25 μg of rhNQO2. Reactions (500 μl) were performed at 30°C in the absence and presence of 10 μM resveratrol for 30 min and then stopped by the addition of ice-cold methanol (500 μl), and samples were immediately analyzed by HPLC at 340 nm.

**Statistical Analysis.** Statistical analysis was performed using one-way analysis of variance followed by appropriate post hoc tests: Dunnett test for comparison of multiple observations to a single control, and Student’s t test for pair-wise comparisons. Data are represented as mean ± S.D. of at least three replicate experiments.

**Results**

**Role of NQO1 in RH1 Toxicity.** We have reported previously the establishment of a pair of isogenic human breast cancer cell lines, the MDA468 and MDA468/NQ16 cells, which differ only in NQO1 activity (Dehn et al., 2004). MDA468 parental cells have a homozygous 2-polymerism in NQO1 and hence nondetectable NQO1 activity because of rapid proteasomal degradation of NQ12 protein. The NQ16 cell line was generated by stable transfection of human wild-type NQO1 (Dehn et al., 2004). In this study, we confirmed previous reports of high levels of NQO1 expression in the NQ16 cell line by immunoblot analysis (data not shown) and NQO1 activity assay (Table 1). As expected, RH1 was significantly more toxic to NQ16 cells than to parental MDA468 cells as measured by both MTT and SRB growth inhibition assay. The IC₅₀ values for RH1 (Table 1) were approximately 15-fold lower in NQ16 cells compared with the IC₅₀ value for the parental MDA468 cells. The difference in RH1 toxicity between MDA468 and NQ16 cells was also confirmed by clonogenic assays (the ratio of sensitivity to RH1 was 44 for the MDA468/NQ16 cell pair; see Fig S1 for clonogenic survival curve). RH1-induced DNA cross-linking was compared in MDA468 and NQ16 cells using the modified comet assay. Treatment of NQ16 cells with 50, 100, and 500 nM RH1 for 2 h resulted in a significant dose-dependent increase in DNA cross-linking (Fig. 1), whereas in MDA468 cells, a small amount of DNA cross-linking could only be observed at the highest RH1 dose (500 nM).

**Role of P450R in RH1 Toxicity.** A wide range of P450R activity was detected in transfected clones generated as described under Materials and Methods. Activity was continu-

**Table 1**

<table>
<thead>
<tr>
<th>Cell Lines</th>
<th>MDA468</th>
<th>NQ16</th>
</tr>
</thead>
<tbody>
<tr>
<td>NQO1 activity (nmol DCPt/min/mg protein)</td>
<td>N.D.</td>
<td>1061.4 ± 50.5</td>
</tr>
<tr>
<td>IC₅₀ (nM) by MTT assay</td>
<td>110.5 ± 13</td>
<td>6.1 ± 0.1*</td>
</tr>
<tr>
<td>IC₅₀ (nM) by SRB assay</td>
<td>99.2 ± 6.7</td>
<td>7.4 ± 1.9*</td>
</tr>
</tbody>
</table>

N.D., not detectable (< 5 nmol DCPt/min/mg protein).

* A significant difference (p < 0.01, Student’s t test) between IC₅₀ values for MDA468 and NQ16 cells.
ously measured in transfected clones to ensure maintenance of stable P450R expression. Immunoblot analysis was also performed to confirm the overexpression of P450R protein in the transfected clones (data not shown). P450R activity levels of parental MDA468 and transfected clones R3, R7, R12, R10, and R5 (in the order of increasing activity) are shown in Fig. 2A. To ensure that the transfected P450R was functioning as a bioreductive enzyme in MDA468 cells, oxygen consumption was measured in parental and P450R-transfected MDA468 cells before and after treatment with 25 μM menadione. An increase in oxygen consumption after menadione treatment indicates the bioreduction of the redox cycling quinone menadione by P450R. All five transfected clones exhibited a significant increase in oxygen consumption after menadione treatment, and the level of increase in oxygen uptake was proportional to P450R activity in all five clones (Fig. 2B). The IC₅₀ values of RH1 for all five P450R clones were determined by both MTT and SRB growth inhibition assay. No correlation was observed between P450R activity and IC₅₀ values for RH1 in all P450R clones when the IC₅₀ values were plotted against P450R activity (Fig. 2, C and D). Three clones with the highest P450R activity, namely R12, R10, and R5, were selected for RH1 genotoxicity analysis. DNA single-strand breaks and cross-linking were measured using the alkaline comet assay and the modified comet assay, respectively. No DNA single-strand breaks could be detected in either parental MDA468 cells or P450R-transfected clones after 2-h RH1 treatment at all doses tested (Fig. 3A). To exclude the possibility of DNA single-strand breaks masked by quick DNA damage repair, formation of DNA single-strand breaks were also monitored after shorter RH1 exposure. In these experiments, DNA single-strand breaks were not observed even at time points as early as 10 min (data not shown). The level of DNA cross-linking was not different between parental MDA468 and P450R-transfected clones at low doses of RH1 exposure (50 and 100 nM). However, when cells were treated with 500 nM RH1 for 2 h, a significant increase in DNA cross-linking in the two clones with the highest P450R activity (clones R10 and R5) relative to parental MDA468 cells was observed (Fig. 3B).

**Role of b5R in RH1 Cytotoxicity.** Three b5R-transfected MDA468 clones were initially selected based on immunoblot analysis (data not shown), and b5R catalytic activity was then continuously measured in transfected clones to ensure the maintenance of stable b5R expression. b5R activity levels of parental MDA468 and b5R-transfected clones H, C, and D (in the order of increasing activity) are shown in Fig. 4A. All three b5R clones exhibited a significant increase in oxygen consumption after menadione treatment, indicating
that the transfected b5R was catalytically active as a bioreductive enzyme in MDA468 cells (Fig. 4B). The IC50 values of RH1 for all three b5R clones were determined by both MTT and SRB growth inhibition assay. No correlation was observed between b5R activity and IC50 values for RH1 in all b5R clones when the IC50 values were plotted against b5R activity (Fig. 4, C and D). The clone with the highest b5R activity, namely clone D, was selected for RH1 genotoxicity analysis. DNA single-strand breaks and cross-linking were measured using the alkaline comet assay and the modified comet assay, respectively. No single-strand breaks could be detected in either parental MDA468 cells or b5R-transfected clone D after 2-h RH1 treatment (Fig. 5A). The level of DNA cross-linking was not different between parental MDA468 and clone D at low doses of RH1 exposure (50 and 100 nM); a small increase in DNA cross-linking in clone D compared with parental MDA468 cells was observed after treatment with 500 nM RH1 for 2 h (Fig. 5B).

**Role of XO in RH1 Bioactivation and Cytotoxicity.** To test whether RH1 could serve as a substrate for XO, the effect of RH1 on the XO-mediated conversion of xanthine to uric acid and the concomitant reduction of RH1 was assessed. The addition of RH1 led to a dose-dependent increase in the rate of both uric acid formation and RH1 consumption (Fig. 6), which was completely inhibited in the presence of 50 μM allopurinol, a potent inhibitor of XO/XDH. However, pretreatment with allopurinol did not decrease RH1 toxicity in MDA468 cells (Fig. S2). XO/XDH levels in MDA468 cells were below detection levels of both colorimetric and fluorescence assays used for detection of XO/XDH activity.

**Role of NQO2 in RH1 Bioactivation and Cytotoxicity.** The ability of purified recombinant human NQO2 to metabolize RH1 was analyzed by HPLC in the presence of the cofactor NRH. As shown in Fig. 7A, RH1 was quickly metabolized within 30 min, accompanied by a concomitant consumption of NRH. The addition of 10 μM resveratrol, a
confirmed NQO2 inhibitor, totally abolished the reduction of RH1 by rhNQO2 (Fig. 7B).

A series of MDA468 cell clones overexpressing NQO2 were then generated by stable transfection. Elevated NQO2 levels were confirmed by both immunoblot analysis (data not shown) and activity assay. NQO2 activity levels of parental MDA468 and transfected clones NQ2C3, NQ2C5, NQ2C4, and NQ2C2 (in the order of increasing activity) are shown in Fig. 8A. The IC50 values for RH1 for all four NQO2 clones were determined by both MTT and SRB growth inhibition assays. A significant correlation \( r^2 = 0.94 \) (MTT), 0.88 (SRB) was observed between NQO2 activity levels and IC50 values for RH1 in all NQO2 clones when the IC50 values were plotted against NQO2 activity (Fig. 8, B and C). In MTT assays, the IC50 value for RH1 was approximately 20-fold lower in NQ2C4 cells compared with the IC50 for the parental MDA468 cells. The difference in RH1 toxicity between MDA468 and the series of NQO2-transfected cells was also confirmed by the clonogenic assay (the ratio of clonogenic sensitivity to RH1 was 11 for the MDA468/NQ2C4 cell pair; see Fig. S1 for clonogenic survival curve). Two clones with medium (NQ2C3) and high (NQ2C4) NQO2 activity were selected for RH1 genotoxicity analysis. A significant dose-dependent increase in DNA cross-linking was observed in both clones after 2-h RH1 treatment (Fig. 8D). The percentage of cross-linked DNA was much higher in clone NQ2C4 (high NQO2 activity level) than in clone NQ2C3 (medium NQO2 activity level).

### Discussion

NQO1 has emerged as a promising target for the design of bioreductive antitumor quinone drugs, and we have reported a relationship between NQO1 levels and susceptibility to RH1 toxicity previously (Winski et al., 2001, Dehn et al., 2004). Using a panel of BE cells (human colon adenocarcinoma) overexpressing a range of NQO1 activity, Winski et al. (2001) found that a threshold of NQO1 activity was needed for RH1-induced toxicity. Using an isogenic cell line pair, MDA468 and MDA468/NQ16 (MDA468 cells stably transfected with NQO1), Dehn et al. (2004) showed that RH1 exhibited antitumor activity in NQ16 cells both in vitro and in vivo (Dehn et al., 2004). Because we were using the MDA468 cell line as the parental cell line in the current study, we first confirmed the significantly higher toxicity of RH1 in NQ16 cells than in MDA468 cells (Table 1 and Fig. 1). The results are consistent with our previous data (Dehn et al., 2004, 2005) and confirm a role for NQO1 in RH1 toxicity.

Although RH1 was discovered to be effectively activated by NQO1, the specificity of RH1 activation by NQO1 has been questioned. A recent study (Hasinoff and Begleiter, 2006) has shown that RH1 can serve as a substrate for P450R; however, Begleiter et al. (2007) did not observe any increase in RH1 toxicity when they overexpressed P450R in the human breast cancer cell line T47D. However, because the T47D cell line has considerable NQO1 activity (Begleiter et al., 2007), the more efficient reduction of RH1 by NQO1 may camouflage any effect of P450R. Kim et al. (2004) used another human breast cancer cell line MDA231, which does not have NQO1 activity, and found that overexpression of P450R had little impact on RH1 toxicity. In our current study, we used a human breast cancer cell line, MDA468, which also has nondetectable NQO1 activity because it carries the homozygous NQO1*2 polymorphism (Siegel et al., 2001; Dehn et al., 2004). We then stably overexpressed the one-electron reductases P450R and b5R and the two-electron reductase NQO2 in the same MDA468 background. The establishment of a series of P450R, b5R, and NQO2 overexpressing clones in the same background allowed us to investigate the possible role...
of P450R, b5R, and NQO2 in RH1-induced DNA damage and growth inhibition. In our study, we selected five stable P450R-transfected clones, three stable b5R-transfected clones, and four stable NQO2-transfected clones to compare with the parental MDA468. To ensure that transfection of the MDA468 cell line with one particular reductase did not alter the level of other reducing enzymes, the enzymatic activity of NQO1, NQO2, P450R, b5R, and XO/XDH was measured in the parental MDA468 and all of the transfected clones. In all of the clones tested, the transfection only elevated the activity of the reductase being transfected without affecting the activity of any other reductases measured (Table S1).

The IC\textsubscript{50} values of RH1 in both P450R- and b5R-transfected clones measured using both MTT and SRB assays were randomly scattered, and no apparent correlation was observed between the activity of these reductases and the IC\textsubscript{50} values of RH1. However, the IC\textsubscript{50} values of RH1 were significantly lower in NQO2-transfected clones compared to the parental MDA468 cells (Fig. 7).

**Fig. 7.** Reduction of RH1 by recombinant human NQO2. RH1 metabolism by NQO2 was analyzed by HPLC after 30-min reaction in the absence (A) and presence (B) of 10 \( \mu \)M resveratrol. A, RH1 and NRH absorbance at 340 nm at time 0 (solid line) and after 30 min of reaction (broken line). B, RH1 and NRH peaks remained unchanged over 30 min in the presence of 10 \( \mu \)M resveratrol. Results shown are representative of three independent experiments.

**Fig. 8.** Characterization of MDA468 cells stably transfected with human NQO2. A, NQO2 activity in parental MDA468 cells and NQO2-transfected clones NQ2C3, NQ2C5, NQ2C4, and NQ2C2. NQO2 activity was measured using the NRH-dependent reduction of menadione. B and C, correlation analysis between NQO2 activity and IC\textsubscript{50} values for RH1 in various NQO2-transfected MDA468 clones. IC\textsubscript{50} values were determined by the MTT assay (B) or the SRB assay (C). IC\textsubscript{50} values are expressed as the mean ± S.D. of at least four separate determinations. NQO2 activity represents the mean of four separate determinations. D, formation of DNA cross-linking in parental and NQO2-transfected MDA468 cells after RH1 treatment. DNA cross-linking was measured by modified comet assay after 2-h treatment with RH1. DNA cross-linking was expressed as the percentage decrease in comet tail moment in RH1-treated cells compared with untreated \( \text{H}_2\text{O}_2 \) (200 \( \mu \)M for 20 min) control. The percentage of DNA in comet tail was also recorded and listed in Table S2. Results are expressed as the mean ± S.D. of three separate determinations. *, significantly different from parental cells with same drug treatment, \( p < 0.05 \); **, \( p < 0.01 \).
observed when IC_{50} values were plotted against P450R or b5R activity. The only P450R-transfected clone that had a lower IC_{50} value than parental MDA468 was R10, and the only b5R-transfected clone with a decreased IC_{50} value was clone C (using the SRB assay). One criticism of isogenic cell pairs is that the expression plasmid containing the cDNA of interest may insert anywhere into the genome and may affect the expression of other proteins. Therefore, by comparing a series of transfected clones rather than using only one clone, we were able to minimize the influence of random insertion during transfection.

To examine the ability of RH1 to induce DNA damage in P450R/b5R-transfected MDA468 cells, we selected three clones with the highest P450R activity and one clone with the highest b5R activity and performed the alkaline comet assay for DNA single-strand breaks and the modified comet assay for DNA cross-linking. The lack of formation of DNA strand breaks by RH1 in the transfected clones was somewhat unexpected, because the RH1 semiquinone free radical generated by one electron reduction would be oxidized back to the quinone form in aerobic conditions, generating reactive oxygen species (Hasinoff et al., 2006, Lusthof et al., 1992), which can cause DNA strand breaks. We found no difference in DNA cross-linking between parental and either P450R- or b5R-transfected MDA468 cells at low RH1 doses (50 and 100 nM). However, a significant increase in DNA cross-linking was observed in clone R10 and R5 (P450R) after 500 nM RH1 treatment for 2 h. However, a concentration of 500 nM RH1 is almost 25 times greater than the IC_{50} value for clone R10 and twice the IC_{50} value for clone R5. Likewise, a nonsignificant increase in DNA cross-linking was observed in clone D (b5R) only at the highest RH1 dose (500 nM, three times the IC_{50} value for clone D). These results indicate that at high drug concentrations, high levels of P450R or b5R activity may contribute to RH1-induced DNA cross-linking, but given the respective IC_{50} values, it seems unlikely that this has any influence on cell death. Although the concentrations of RH1 have not been reported in human or animal tumors after RH1 administration, pharmacokinetic studies in mice have shown that RH1 has a short plasma half-life (<5 min; Lodman et al., 2000); in addition, experiments that examined DNA cross-linking in human peripheral blood mononuclear cells after RH1 treatment indicated that 100% cross-linking could be achieved in these cells at RH1 concentrations near 50 nM (Danson et al., 2007). These data suggest that high levels of RH1 in tumors are unlikely because of rapid clearance and potential toxicities. We therefore reasoned that neither P450R nor b5R plays a significant role in activation of RH1 in cancer cells with normal levels of P450R and b5R activity, especially when considerable levels of NQO1 activity is also present. According to a reductase enzyme activity screen across the NCI tumor cell line panel (Fitzsimmons et al., 1996), the mean P450R activity is 14.8 nmol/min/mg protein, and the mean b5R activity is 38.0 nmol/min/mg protein, both of which are similar to MDA468 parental cells and far less than the transfected clones. In contrast, NQO1 activities in the NCI tumor cell panel range from 0 to 5000 nmol/min/mg protein with a mean of 199.5 nmol/min/mg protein. Such high levels of NQO1 would be expected to efficiently metabolize RH1.

Although our enzymatic studies showed that RH1 could serve as a substrate for xanthine oxidase in vitro, pretreatment of MDA468 cells with the XO/XDH inhibitor allopurinol failed to protect the cells from RH1 toxicity. We could not detect any XO/XDH activity in MDA468 cells, in agreement with previous data from our lab which showed that XO activity was nondetectable in HT-29 and BE human colon carcinoma cells (Winski et al., 1998). XO activity screening for the NCI tumor cell line panel is not available at present. Therefore, the overexpression of XO in MDA468 cells was not pursued.

An important finding of the current study is that we have shown, for the first time, that NQO2 can play an important role in RH1 bioactivation and cytotoxicity in tumor cells. NQO2 differs from NQO1 in that it uses dihydronicotinamide riboside (NRH) rather than NAD(P)H as an electron donor (Wu et al., 1997). As expected, RH1 was a substrate for purified recombinant human NQO2 using NRH as a cofactor. MDA468 cells stably transfected with NQO2 were more susceptible to RH1-induced growth inhibition and DNA cross-linking, with a strong correlation between NQO2 activity levels and IC_{50} values for RH1 in all NQO2-transfected clones. These results strongly suggest that NQO2 is capable of mediating RH1 bioactivation and cytotoxicity in tumor cells. The possibility of limited NRH availability in cells has been recognized (Knox et al., 2000). However, in our studies transfected NQO2 did not need exogenous NRH to bioactivate RH1 in the MDA468 cell system. This suggests that either the MDA468 cells have sufficient NRH to catalyze turnover of NQO2 or that other pyridine nucleotides in the cell can serve as a cofactor for NQO2. It is interesting that recent work showed that NQO2 can catalyze the reduction of mitomycin C using NADH as a cofactor (Jamsion et al., 2006). The respective efficiencies of NQO1 and NQO2 at bioactivation of RH1 require further study. However, because NQO2 protein and activity levels are normally very low in solid tumors (Knox et al., 2000), it is possible that the contribution of NQO2 to RH1 toxicity could be overridden by NQO1. An important implication of our work is that NQO2 may be an important determinant of RH1 bioactivation and antitumor effect particularly in tumors that have low NQO1 levels. Leukemia and lymphoma cell lines are deficient in NQO1 levels (Fitzsimmons et al., 1996; Tudor et al., 2005) but are very sensitive to RH1 treatment (Tudor et al., 2005). NQO2 levels have been found previously to be high in the K562 leukemia cell line (Buryanovskyk et al., 2004), and this observation has been recently confirmed in two independent studies (Bantscheff et al., 2007; Rix et al., 2007). We have also performed immunoblot analysis of a number of leukemia lines (KG1A, K562, Jurkat, MOLT4, and HL60) and have found NQO2 protein levels to be high across the panel (C. Yan, D. Siegel, J. Kepa, D. Ross, unpublished data). The elevated NQO2 levels in leukemia cell lines may explain the observed sensitivity of these tumors to RH1.

In conclusion, our study confirmed that NQO1 is an important reductase catalyzing the bioactivation of RH1 in tumor cells. P450R and b5R may contribute to the toxicity of RH1 in tumor cells at very high enzyme activity levels and high drug doses. However, the importance of P450R and b5R in the bioactivation and cytotoxicity of RH1 would be expected to be minor in cancer cells with normal levels of b5R and P450R activity. In addition, RH1 can serve as a substrate for XO, but XO was not a major contributor to RH1 toxicity in our studies. It is noteworthy that NQO2 was found to be strongly
associated with RH1 bioactivation and cytotoxicity in tumor cells. These results suggest that in addition to NQO1, levels of NQO2 have to be considered as a potential biomarker of RH1 efficacy in human tumors.

References


Addenda: correspondence to: Dr. David Ross, Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Denver, C-218, 12700 East 19th Avenue, Denver, CO 80245. E-mail: david.ross@ucdenver.edu